What causes hot flushes? the neuroendocrine origin of vasomotor symptoms in the menopause

Gynecological Endocrinology

Volumn 25, Issue 5, 2009, Pages 303-314

  Rossmanith, Winfried G ^a,b   Ruebberdt, Wiebke ^c  

^a Diakonissenkrankenhaus Karlsruhe ^*  (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c Wyeth Pharma GmbH   (Germany)

Author keywords

Menopause; Neuroendocrinology; Neurotransmitters; Sex steroids; Temperature regulation

Indexed keywords

AROMATASE INHIBITOR; CIMICIFUGA RACEMOSA EXTRACT; CITALOPRAM; CLONIDINE; DESVENLAFAXINE; ESTROGEN; ESTROGEN RECEPTOR; FLUOXETINE; FOLLITROPIN; GABAPENTIN; GONADORELIN AGONIST; GONADOTROPIN; LUTEINIZING HORMONE; MIRTAZAPINE; NORADRENALIN; PAROXETINE; PHYTOESTROGEN; PLACEBO; PROGESTERONE; RALOXIFENE; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SEX HORMONE; TAMOXIFEN; VENLAFAXINE;

ADAPTATION; BODY TEMPERATURE; CENTRAL NERVOUS SYSTEM; CLIMACTERIUM; CLINICAL TRIAL; CORE TEMPERATURE; DISEASE MODEL; DIZZINESS; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; EDEMA; ESTROGEN BLOOD LEVEL; FOLLITROPIN BLOOD LEVEL; GENE EXPRESSION REGULATION; GONADOTROPIN BLOOD LEVEL; HEAT SENSITIVITY; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MENOPAUSAL SYNDROME; MENOPAUSE; MOLECULAR MECHANICS; NAUSEA; NEUROMODULATION; NEUROPATHOLOGY; NEUROTRANSMITTER RELEASE; NIGHT SWEAT; NONHUMAN; PERCEPTIVE THRESHOLD; PERIPHERAL VASCULAR SYSTEM; PLACEBO EFFECT; PREOPTIC AREA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SHIVERING; SKIN BLOOD FLOW; SLEEP DISORDER; SOMNOLENCE; SWEATING; THERMOREGULATION; TREATMENT DURATION; TREATMENT OUTCOME; VASOMOTOR DISORDER; VASOMOTOR REFLEX; XEROSTOMIA;

ADAPTATION, PHYSIOLOGICAL; BODY TEMPERATURE REGULATION; ESTROGENS; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; NEUROTRANSMITTER AGENTS; VASOMOTOR SYSTEM;

EID: 67651089721     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590802632514     Document Type: Review

References (132)

1. National Institutes of Health State-of-the-Science Conference statement. Management of Menopause-Related Symptoms. Ann Intern Med 2005;142:1003-1013.
2. Kuhl H. Klimakterium, Postmenopause und Hormonsubstitution, UNI-MED Verlag Bremen Kap. 3.2.(S. 50 ff.), 2. Auflage. 2001.
3. Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad.Sci 1990;592:52-86.
4. Woodward S, Freedman RR. The thermoregulatory effects of menopausal hot flashes on sleep. Sleep 1994;17:497-501.
5. Joffe H, Hall JE, Soares CN, Hennen J, Reilly CJ, Carlson K, Cohen LS. Vasomotor symptoms are associated with depression in perimenopausal women seeking primary care. Menopause 2002;9:392-398.
6. Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes 2005;3:47.
7. Mom CH, Buijs C, Willemse PH, Mourits MJ, de Vries EG. Hot flushes in breast cancer patients. Crit Rev.Oncol Hematol. 2006;57:63-77.
8. Ness J, Aronow WS, Beck G. Menopausal symptoms after cessation of hormone replacement therapy. Maturitas 2006;53:356-361.
9. Baerug U, Winge T, Nordland G, Faber-Swensson E, Heldaas K, Norling B, Larsen S, Arce JC. Do combinations of 1 mg estradiol and low doses of NETA effectively control menopausal symptoms? Climacteric 1998;1:219-228.
10. Hendrix SL. Bilateral oophorectomy and premature menopause. Am J Med 2005;118 Suppl 12B:131-135.
11. Randolph JF, Jr., Sowers M, Bondarenko I, Gold EB, Greendale GA, Bromberger JT, Brockwell SE, Matthews KA. The relationship of longitudinal change in reproductive hormones and vasomotor symptoms during the menopausal transition. J Clin Endocrinol Metab 2005;90:6106-6112.
12. Overlie I, Moen MH, Holte A, Finset A. Androgens and estrogens in relation to hot flushes during the menopausal transition. Maturitas 2002;41:69-77.
13. Berendsen HH. The role of serotonin in hot flushes. Maturitas 2000;36:155-164.
14. Deecher DC. Physiology of thermoregulatory dysfunction and current approaches to the treatment of vasomotor symptoms. Expert Opin Investig Drugs 2005;14:435-448.
15. Freedman RR. Physiology of hot flashes. Am J Hum Biol 2001;13:453-464.
16. Rodstrom K, Bengtsson C, Lissner L, Milsom I, Sundh V, Bjorkelund C. A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century. Menopause 2002;9:156-161.
17. Avis NE, Brockwell S, Colvin A. A universal menopausal syndrome? Am J Med 2005;118 Suppl 12B:37-46.
18. Guthrie JR, Dennerstein L, Taffe JR, Lehert P, Burger HG. The menopausal transition: a 9-year prospective population-based study. The Melbourne Women's Midlife Health Project. Climacteric 2004;7:375-389.
19. North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004;11:11-33.
20. Charkoudian N. Skin blood flow in adult human thermo-regulation: how it works, when it does not, and why. Mayo Clin Proc 2003;78:603-612.
21. Cabanac M, Massonnet B. Thermoregulatory responses as a function of core temperature in humans. J Physiol 1977;265:587-596.
22. Hensel H. Neural processes in thermoregulation. Physiol Rev. 1973;53:948-1017.
23. Boulant JA, Dean JB. Temperature receptors in the central nervous system. Annu Rev Physiol 1986;48:639-654.
24. Romanovsky AA. Thermoregulation: some concepts have changed. Functional architecture of the thermoregulatory system. Am J Physiol Regul Integr Comp Physiol 2007;292: R37-R46.
25. Simon E. The enigma of deep-body thermosensory specificity. Int J Biometeorol 2000;44:105-120.
26. Frank SM, Raja SN, Bulcao CF, Goldstein DS. Relative contribution of core and cutaneous temperatures to thermal comfort and autonomic responses in humans. J Appl Physiol 1999;86:1588-1593.
27. Crawshaw L, Grahn D, Wollmuth L, Simpson L. Central nervous regulation of body temperature in vertebrates: comparative aspects. Pharmacol Ther 1985;30:19-30.
28. Boulant JA. Role of the preoptic-anterior hypothalamus in thermoregulation and fever. Clin Infect Dis 2000;31 Suppl 5:S157-S161.
29. Zhang YH, Yamada K, Hosono T, Chen XM, Shiosaka S, Kanosue K. Efferent neuronal organization of thermoregulatory vasomotor control. Ann N Y Acad Sci 1997;813:117-122.
30. Bruck K, Zeisberger E. Adaptive changes in thermoregulation and their neuropharmacological basis. Pharmacol Ther 1987;35:163-215.
31. Gundlah C, Pecins-Thompson M, Schutzer WE, Bethea CL. Ovarian steroid effects on serotonin 1A, 2A and 2C receptor mRNA in macaque hypothalamus. Brain Res Mol Brain Res 1999;63:325-339.
32. Bethea CL, Lu NZ, Gundlah C, Streicher JM. Diverse actions of ovarian steroids in the serotonin neural system. Front Neuroendocrinol 2002;23:41-100.
33. Karkanias GB, Ansonoff MA, Etgen AM. Estradiol regulation of alpha 1b-adrenoceptor mRNA in female rat hypothalamus-preoptic area. J Neuroendocrinol 1996;8:449-455.
34. Karkanias GB, Li CS, Etgen AM. Estradiol reduction of alpha 2-adrenoceptor binding in female rat cortex is correlated with decreases in alpha 2A/D-adrenoceptor messenger RNA. Neuroscience 1997;81:593-597.
35. Petitti N, Etgen AM. Alpha 1-adrenoceptor augmentation of beta-stimulated cAMP formation is enhanced by estrogen and reduced by progesterone in rat hypothalamic slices. J Neurosci. 1990;10:2842-2849.
36. Martin GR. Vascular receptors for 5-hydroxytryptamine: distribution, function and classification. Pharmacol Ther 1994;62:283-324.
37. Abdelmawla AH, Langley RW, Szabadi E, Bradshaw CM. Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein. Br J Clin Pharmacol 1999;48:345-354.
38. Freedman RR. Hot flashes: behavioral treatments, mechanisms, and relation to sleep. Am J Med 2005;118 Suppl 12B:124-130.
39. Kurz A, Sessler DI, Tayefeh F, Goldberger R. Poikilothermia syndrome. J Intern Med 1998;244:431-436.
40. Sullivan F, Hutchinson M, Bahandeka S, Moore RE. Chronic hypothermia in multiple sclerosis. J Neurol Neuro-surg Psychiatry 1987;50:813-815.
41. White KD, Scoones DJ, Newman PK. Hypothermia in multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;61:369-375.
42. Edwards S, Lennox G, Robson K, Whiteley A. Hypothermia due to hypothalamic involvement in multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;61:419-420.
43. Crompton MR. Hypothalamic lesions following closed head injury. Brain 1971;94:165-172.
44. Thompson HJ, Tkacs NC, Saatman KE, Raghupathi R, McIntosh TK. Hyperthermia following traumatic brain injury: a critical evaluation. Neurobiol Dis 2003;12:163-173.
45. Couzi RJ, Helzlsouer KJ, Fetting JH. Prevalence of meno-pausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol 1995;13:2737-2744.
46. Fallowfield L, Fleissig A, Edwards R, West A, Powles TJ, Howell A, Cuzick J. Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol 2001;19:1885-1892.
47. Land SR, Wickerham DL, Costantino JP, Ritter MW, Vogel VG, Lee M, Pajon ER, Wade JL, III, Dakhil S, Lockhart JB, Jr., et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2742-2751.
48. Jordan VC. SERMs: meeting the promise of multifunctional medicines. J Natl Cancer Inst 2007;99:350-356.
49. Holzbeierlein JM, Castle EP, Thrasher JB. Complications of androgen-deprivation therapy for prostate cancer. Clin Prostate Cancer 2003;2:147-152.
50. Bachmann GA. Menopausal vasomotor symptoms: a review of causes, effects and evidence-based treatment options. J Reprod Med 2005;50:155-165.
51. Santoro N. The menopausal transition. Am J Med 2005;118 Suppl 12B:8-13.
52. Burger HG, Dudley EC, Robertson DM, Dennerstein L. Hormonal changes in the menopause transition. Recent Prog Horm Res 2002;57:257-275.
53. Santoro N, Brown JR, Adel T, Skurnick JH. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab 1996;81:1495-1501.
54. Nelson HD, Haney E, Humphrey L, Miller J, Nedrow A, Nicolaidis C, Vesco K, Walker M, Bougatsos C, Nygren P. Management of menopause-related symptoms. Evid Rep Technol Assess (Summ.) 2005;1-6.
55. Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. Arch Gen Psychiatry 2006;63:385-390.
56. Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 2006;63:375-382.
57. Dennerstein L, Smith AM, Morse CA, Burger HG. Sexuality and the menopause. J Psychosom Obstet Gynaecol 1994;15:59-66.
58. Shaver JL, Paulsen VM. Sleep, psychological distress, and somatic symptoms in perimenopausal women. Fam Pract Res J 1993;13:373-384.
59. Rossmanith WG, Liu CH, Laughlin GA, Mortola JF, Suh BY, Yen SS. Relative changes in LH pulsatility during the menstrual cycle: using data from hypogonadal women as a reference point. Clin Endocrinol (Oxf) 1990;32:647-660.
60. Rossmanith WG, Ulrich U. Neuroendokrine Aspekte der Hormonregulation in Peri- und Postmenopause. Aktuelle Hormontherapie in der Gynäkologie (Kiesel L., Rabe T., Runnebaum B.) Hrsg, München: Zuckerschwerdt Verlag (103) 1993.
61. Kuhl H, Taubert HD. Endokrine Veränderungen, Das Klimakterium, Stuttgart, New York Thieme Verlag (128) 1987.
62. Casper RF, Yen SS, Wilkes MM. Menopausal flushes: a neuroendocrine link with pulsatile luteninizing hormone secreation. Science 1979;205:823-825.
63. Tataryn IV, Lomax P, Bajorek JG, Chesarek W, Meldrum DR, Judd HL. Postmenopausal hot flushes: a disorder of thermoregulation. Maturitas 1980;2:101-107.
64. Freedman Robert R, Woodward S. Altered Shivering Threshold in Postmenopausal Women with Hot Flashes. Menopause: The Journal of the North American Menopause Society 1995;2(3):163-168.
65. Freedman RR, Norton D, Woodward S, Cornelissen G. Core body temperature and circadian rhythm of hot flashes in menopausal women. J Clin Endocrinol Metab 1995;80:2354-2358.
66. Freedman RR, Woodward S. Core body temperature during menopausal hot flushes. Fertil Steril 1996;65:1141-1144.
67. Freedman RR, Krell W. Reduced thermoregulatory null zone in postmenopausal women with hot flashes. Am J Obstet Gynecol 1999;181:66-70.
68. Brooks EM, Morgan AL, Pierzga JM, Wladkowski SL, O'Gorman JT, Derr JA, Kenney WL. Chronic hormone replacement therapy alters thermoregulatory and vasomotor function in postmenopausal women. J Appl Physiol 1997;83:477-484.
69. Joswig M, Hach-Wunderle V, Ziegler R, Nawroth PP. Postmenopausal hormone replacement therapy and the vascular wall: mechanisms of 17 beta-estradiol's effects on vascular biology. Exp Clin Endocrinol Diabetes 1999;107: 477-487.
70. Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002;77:1207-1218.
71. Nelson HD, Vesco KK, Haney E. Clonidine, gabapentin, and some SSRIs effective for hot flashes. J Fam Pract 2006;55:662.
72. Clayden JR. Effect of clonidine on menopausal flushing. Lancet 1972;2:1361.
73. Williams CW. Clonidine in treatment of menopausal flushing. Lancet 1973;1:1388.
74. Clayden JR, Bell JW, Pollard P. Menopausal flushing: double-blind trial of a non-hormonal medication. Br Med J 1974;1:409-412.
75. Deecher DC, Alfinito PD, Leventhal L, Cosmi S, Johnston GH, Merchenthaler I, Winneker R. Alleviation of thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized rodent models. Endocrinology 2007;148: 1376-1383.
76. Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, Nicolaidis C, Walker M, Humphrey L. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006;295:2057-2071.
77. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, Novotny PJ, Dakhil SR, Rodger K, Rummans TA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059-2063.
78. Stearns V, Slack R, Greep N, Henry-Tilman R, Osborne M, Bunnell C, Ullmer L, Gallagher A, Cullen J, Gehan E, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol 2005;23:6919-6930.
79. Gould E, Woolley CS, Frankfurt M, McEwen BS. Gonadal steroids regulate dendritic spine density in hippocampal pyramidal cells in adulthood. J Neurosci 1990;10:1286-1291.
80. McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocr Rev 1999;20:279-307.
81. McEwen BS. Invited review: Estrogens effects on the brain: multiple sites and molecular mechanisms. J Appl Physiol 2001;91:2785-2801.
82. Woolley CS, McEwen BS. Roles of estradiol and progesterone in regulation of hippocampal dendritic spine density during the estrous cycle in the rat. J Comp Neurol 1993;336:293-306.
83. Genazzani AR, Pluchino N, Luisi S, Luisi M. Estrogen, cognition and female ageing. Hum Reprod Update 2007;13:175-187.
84. Gibbs RB. Levels of trkA and BDNF mRNA, but not NGF mRNA, fluctuate across the estrous cycle and increase in response to acute hormone replacement. Brain Res 1998;787:259-268.
85. Birge SJ. Estrogen and the brain: implications for menopause management. Menopause: The State of the Art - in Research and Management 2002;191-195.
86. McEwen B. Estrogen actions throughout the brain. Recent Prog Horm Res 2002;57:357-384.
87. Bethea CL, Gundlah C, Mirkes SJ. Ovarian steroid action in the serotonin neural system of macaques. Novartis Found Symp 2000;230:112-130.
88. Gundlah C, Kohama SG, Mirkes SJ, Garyfallou VT, Urbanski HF, Bethea CL. Distribution of estrogen receptor beta (ERbeta) mRNA in hypothalamus, midbrain and temporal lobe of spayed macaque: continued expression with hormone replacement. Brain Res Mol Brain Res 2000;76: 191-204.
89. Bethea CL, Brown NA, Kohama SG. Steroid regulation of estrogen and progestin receptor messenger ribonucleic acid in monkey hypothalamus and pituitary. Endocrinology 1996;137:4372-4383.
90. Osterlund MK, Gustafsson JA, Keller E, Hurd YL. Estrogen receptor beta (ERbeta) messenger ribonucleic acid (mRNA) expression within the human forebrain: distinct distribution pattern to ERalpha mRNA. J Clin Endocrinol Metab 2000;85:3840-3846.
91. Temel S, Lin W, Lakhlani S, Jennes L. Expression of estrogen receptor-alpha and cFos in norepinephrine and epinephrine neurons of young and middle-aged rats during the steroid-induced luteinizing hormone surge. Endocrinology 2002;143:3974-3983.
92. Lu H, Ozawa H, Nishi M, Ito T, Kawata M. Serotonergic neurones in the dorsal raphe nucleus that project into the medial preoptic area contain oestrogen receptor beta. J Neuroendocrinol 2001;13:839-845.
93. Kallo I, Liposits Z, Flerko B, Coen CW. Immunocytochemical characterization of afferents to estrogen receptor-containing neurons in the medial preoptic area of the rat. Neuroscience 1992;50:299-308.
94. Maswood N, Cosmi S, Alfinito PD, Leventhal L, Deecher DC. The role of the selective serotonin reuptake inhibitor fluoxetine in temperature regulation in ovariectomized rat models. Neuroendocrinology 2006;84:330-338.
95. Bethea CL, Pecins-Thompson M, Schutzer WE, Gundlah C, Lu ZN. Ovarian steroids and serotonin neural function. Mol Neurobiol 1998;18:87-123.
96. Amin Z, Canli T, Epperson CN. Effect of estrogen-serotonin interactions on mood and cognition. Behav Cogn Neurosci Rev 2005;4:43-58.
97. Herbison AE, Simonian SX, Thanky NR, Bicknell RJ. Oestrogen modulation of noradrenaline neurotransmission. Novartis Found Symp 2000;230:74-85.
98. Etgen AM, Ansonoff MA, Quesada A. Mechanisms of ovarian steroid regulation of norepinephrine receptor-mediated signal transduction in the hypothalamus: implications for female reproductive physiology. Horm Behav 2001;40:169-177.
99. Genazzani AR, Lucchesi A, Stomati M, Catarsi S, Genazzani AD, Criscuolo M, Petraglia F. Effects of sex steroid hormones on the neuroendocrine system. Eur J Contracept Reprod Health Care 1997;2:63-69.
100. Pecins-Thompson M, Brown NA, Kohama SG, Bethea CL. Ovarian steroid regulation of tryptophan hydroxylase mRNA expression in rhesus macaques. J Neurosci 1996;16:7021-7029.
101. Gundlah C, Alves SE, Clark JA, Pai LY, Schaeffer JM, Rohrer SP. Estrogen receptor-beta regulates tryptophan hydroxylase-1 expression in the murine midbrain raphe. Biol Psychiatry 2005;57:938-942.
102. Sanchez RL, Reddy AP, Centeno ML, Henderson JA, Bethea CL. A second tryptophan hydroxylase isoform, TPH-2 mRNA, is increased by ovarian steroids in the raphe region of macaques. Brain Res Mol Brain Res 2005;135:194-203.
103. Hiroi R, McDevitt RA, Neumaier JF. Estrogen selectively increases tryptophan hydroxylase-2 mRNA expression in distinct subregions of rat midbrain raphe nucleus: association between gene expression and anxiety behavior in the open field. Biol Psychiatry 2006;60:288-295.
104. Bethea CL, Mirkes SJ, Shively CA, Adams MR. Steroid regulation of tryptophan hydroxylase protein in the dorsal raphe of macaques. Biol Psychiatry 2000;47:562-576.
105. Gundlah C, Lu NZ, Bethea CL. Ovarian steroid regulation of monoamine oxidase-A and -B mRNAs in the macaque dorsal raphe and hypothalamic nuclei. Psychopharmacology (Berl) 2002;160:271-282.
106. Le Saux M, Di PT. Changes in 5-HT1A receptor binding and G-protein activation in the rat brain after estrogen treatment: comparison with tamoxifen and raloxifene. J Psychiatry Neurosci 2005;30:110-117.
107. Lu NZ, Bethea CL. Ovarian steroid regulation of 5-HT1A receptor binding and G protein activation in female monkeys. Neuropsychopharmacology 2002;27:12-24.
108. Serova L, Rivkin M, Nakashima A, Sabban EL. Estradiol stimulates gene expression of norepinephrine biosynthetic enzymes in rat locus coeruleus. Neuroendocrinology 2002;75:193-200.
109. Serova LI, Maharjan S, Huang A, Sun D, Kaley G, Sabban EL. Response of tyrosine hydroxylase and GTP cyclohydrolase I gene expression to estrogen in brain catecholaminergic regions varies with mode of administration. Brain Res 2004;1015:1-8.
110. Karkanias GB, Etgen AM. Estradiol reduction of the agonist high affinity form of the alpha 2-adrenoceptor in the hypothalamus of female rats: identification as the alpha 2D subtype. Mol Pharmacol 1994;45:509-516.
111. Burger HG. The endocrinology of the menopause. Maturitas 1996;23:129-136.
112. Haimov-Kochman R, Barak-Glantz E, Arbel R, Leefsma M, Brzezinski A, Milwidsky A, Hochner-Celnikier D. Gradual discontinuation of hormone therapy does not prevent the reappearance of climacteric symptoms: a randomized prospective study. Menopause 2006;13:370-376.
113. Farquhar CM, Marjoribanks J, Lethaby A, Lamberts Q, Suckling JA. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2005;CD004143.
114. Johnson SR, Ettinger B, Macer JL, Ensrud KE, Quan J, Grady D. Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol. Obstet Gynecol 2005;105:779-787.
115. Lacey JV, Jr., Brinton LA, Leitzmann MF, Mouw T, Hollenbeck A, Schatzkin A, Hartge P. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst 2006;98:1397-1405.
116. North American Menopause Society. Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 position statement of The North American Menopause Society. Menopause 2004;11:589-600.
117. DGGG (Deutsche Gesellschaft für Gynäkologie und Geburtshilfe). Leitlinien der Hormontherapie in der Peri- und Postmenopause. In Vorbereitung, DGGG. 2009.
118. Pines A, Sturdee DW, Birkhauser MH, Schneider HP, Gambacciani M, Panay N. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007;10:181-194.
119. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003;289:2827-2834.
120. Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, Halyard MY, Pruthi S, Novotny PJ, Rummans TA. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20:1578-1583.
121. Nappi RE, Malavasi B, Brundu B, Facchinetti F. Efficacy of Cimicifuga racemosa on climacteric complaints: a randomized study versus low-dose transdermal estradiol. Gynecol Endocrinol 2005;20:30-35.
122. Ma J, Drieling R, Stafford RS. US women desire greater professional guidance on hormone and alternative therapies for menopause symptom management. Menopause 2006;13:506-516.
123. Caserta L, Caserta R, Torella M, Nappo C, De LD, Panariello S. [The effects of phytoestrogen therapy on the endometrium in postmenopausal women]. Minerva Ginecol 2005;57:551-555.
124. Alfinito PD, Huselton C, Chen X, Deecher DC. Pharmaco-kinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succi-nate in ovariectomized Sprague-Dawley rats. Brain Res 2006;1098:71-78.
125. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH. Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 2006;318:657-665.
126. Archer, David F, DuPont, Caroline M, Pickar, James H, Olivier, Sophie, Constantine, Ginger D. Desvenlafaxine Succinate is Effective in the Treatment of Menopausal Vasomotor Symptoms. 55th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists, San Diego, California (Posterpräsentation) 2007.
127. Gass Margery, Olivier, Sophie, Constantine, Ginger D. Efficacy and Safety of Desvenlafaxine Succinate for treatment of Menopausal Vasomotor Symptoms. 55th Annual Meeting of the American College of Obstetricians and Gynecologists (ACOG) San Diego, California, 2007.
128. Loprinzi CL, Barton DL, Rhodes D. Management of hot flashes in breast-cancer survivors. Lancet Oncol 2001;2:199-204.
129. Loibl S, Schwedler K, von MG, Strohmeier R, Mehta KM, Kaufmann M. Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients - a double-blind, randomized study. Ann Oncol. 2007;18:689-693.
130. Pandya KJ, Morrow GR, Roscoe JA, Zhao H, Hickok JT, Pajon E, Sweeney TJ, Banerjee TK, Flynn PJ. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005;366:818-824.
131. Goldberg RM, Loprinzi CL, O'Fallon JR, Veeder MH, Miser AW, Mailliard JA, Michalak JC, Dose AM, Rowland KM, Jr., Burnham NL. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994;12:155-158.
132. Guyton AC, Hall JE. Body temperature, temperature regulation, and fever. Textbook of Medical Physiology. 11th ed., Philadelphia, PA (Elsevier Saunders), 2006;889-901.